Osteocalcin Antibody [G12E1] | Primary Antibodies

Application: Reactivity: Human

Lane 1: Human Osteocalcin recombinant protein

Usage Information

Dilution
WB1:1000 - 1:10000

Application
WB

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
11 kDa 19 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Positive Control	Human articular cartilage tissue
Negative Control

Datasheet & SDS

Biological Description

Specificity
Osteocalcin Antibody [G12E1] detects endogenous levels of total Osteocalcin protein.

Clone
G12E1

Synonym(s)
Osteocalcin, Bone Gla protein, Gamma-carboxyglutamic acid-containing protein, BGP, BGLAP

Background
Osteocalcin (OCN), also known as bone gamma-carboxyglutamic acid protein (BGLAP), is a 49-amino-acid, ~5.6 kDa non-collagenous protein produced by osteoblasts, functioning both as a critical regulator of bone matrix organization and as a hormone that links bone remodeling to energy and reproductive metabolism. It is encoded by the BGLAP gene and synthesized as a pre-propeptide that is processed into a mature form containing three vitamin K–dependent γ-carboxylated glutamate (Gla) residues. These Gla residues confer a high negative charge, enabling strong binding to calcium ions and hydroxyapatite crystals within bone, thereby allowing carboxylated osteocalcin to organize mineral deposition on collagen fibrils and enhance bone strength and fracture resistance. The undercarboxylated form, with reduced bone affinity, is preferentially released into the circulation, where it acts as an endocrine ligand. Osteocalcin activates G protein–coupled receptors such as GPRC6A on pancreatic β-cells, adipocytes, skeletal muscle, and Leydig cells to stimulate insulin secretion and β-cell proliferation, enhance adiponectin production and insulin sensitivity, promote glucose and fatty acid utilization, and increase testosterone synthesis, positioning bone as a regulator of glucose homeostasis, energy expenditure, and male fertility. Osteocalcin also signals through GPR158 in the brain, modulating neurotransmitter synthesis and cognitive function. Clinically, serum osteocalcin serves as a dynamic marker of bone formation and turnover in osteoporosis and metabolic bone diseases, and changes in its levels or carboxylation status are associated with type 2 diabetes, obesity, cardiovascular disease, and potentially neuropsychiatric conditions.

Background

Osteocalcin (OCN), also known as bone gamma-carboxyglutamic acid protein (BGLAP), is a 49-amino-acid, ~5.6 kDa non-collagenous protein produced by osteoblasts, functioning both as a critical regulator of bone matrix organization and as a hormone that links bone remodeling to energy and reproductive metabolism. It is encoded by the BGLAP gene and synthesized as a pre-propeptide that is processed into a mature form containing three vitamin K–dependent γ-carboxylated glutamate (Gla) residues. These Gla residues confer a high negative charge, enabling strong binding to calcium ions and hydroxyapatite crystals within bone, thereby allowing carboxylated osteocalcin to organize mineral deposition on collagen fibrils and enhance bone strength and fracture resistance. The undercarboxylated form, with reduced bone affinity, is preferentially released into the circulation, where it acts as an endocrine ligand. Osteocalcin activates G protein–coupled receptors such as GPRC6A on pancreatic β-cells, adipocytes, skeletal muscle, and Leydig cells to stimulate insulin secretion and β-cell proliferation, enhance adiponectin production and insulin sensitivity, promote glucose and fatty acid utilization, and increase testosterone synthesis, positioning bone as a regulator of glucose homeostasis, energy expenditure, and male fertility. Osteocalcin also signals through GPR158 in the brain, modulating neurotransmitter synthesis and cognitive function. Clinically, serum osteocalcin serves as a dynamic marker of bone formation and turnover in osteoporosis and metabolic bone diseases, and changes in its levels or carboxylation status are associated with type 2 diabetes, obesity, cardiovascular disease, and potentially neuropsychiatric conditions.

References
https://pubmed.ncbi.nlm.nih.gov/25577163/ https://pubmed.ncbi.nlm.nih.gov/26055108/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%